CP-675,206

DRUG13 trials

Sponsors

AstraZeneca, Jonsson Comprehensive Cancer Center, Pfizer, AHS Cancer Control Alberta, University Health Network, Toronto

Conditions

Advanced Unresectable MelanomaCarcinoma, Non-small-cell LungCarcinoma, Renal CellColorectal NeoplasmsHuman Immunodeficiency VirusMalignant MelanomaMelanomaMelanoma (Skin)

Phase 1

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

CompletedNCT00372853

AstraZenecaCarcinoma, Renal Cell

Start: 2006-11-30End: 2010-05-31Updated: 2012-06-06

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

CompletedNCT00431275

AstraZenecaMelanoma

Start: 2006-06-30End: 2008-02-29Updated: 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

TerminatedNCT00585000

AstraZenecaMelanoma

Start: 2007-12-31End: 2010-01-31Updated: 2012-06-06

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

TerminatedNCT01334099

University Health Network, TorontoMetastatic Breast Cancer

Start: 2010-07-31Updated: 2015-06-22

Phase 2

CP-675,206 In Patients With Advanced Melanoma

CompletedNCT00086489

AstraZenecaMalignant Melanoma

Start: 2003-08-31End: 2009-05-31Updated: 2012-06-06

Study of CP-675,206 in Refractory Melanoma

CompletedNCT00254579

AstraZenecaRefractory Melanoma

Start: 2005-12-31End: 2009-12-31Updated: 2012-06-07

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00312975

AstraZenecaCarcinoma, Non-small-cell Lung

Start: 2006-05-31End: 2010-02-28Updated: 2012-06-07

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

CompletedNCT00313794

AstraZenecaColorectal Neoplasms

Start: 2006-05-31End: 2008-06-30Updated: 2012-06-07

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

CompletedNCT00471887

Jonsson Comprehensive Cancer CenterMelanoma (Skin)

Start: 2007-01-31End: 2015-03-31Updated: 2020-10-26

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

WithdrawnNCT00488995

PfizerHuman Immunodeficiency Virus

Start: 2007-07-31Updated: 2015-03-11

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

CompletedNCT01034787

AHS Cancer Control AlbertaUveal Melanoma

Start: 2009-08-17End: 2017-08-08Updated: 2017-10-27

Phase 3

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

CompletedNCT00257205

AstraZenecaMelanoma

Start: 2006-03-31End: 2010-08-31Updated: 2012-07-02

Unknown Phase

Treatment Use Study for Advanced Melanoma.

PfizerAdvanced Unresectable Melanoma

Start: 2008-05-31Updated: 2009-12-14

Related Papers

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status.

2019-04-1217 citations

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Journal for ImmunoTherapy of Cancer2018-09-1848 citations

Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab.

Journal of Clinical Oncology2017-03-012 citations

Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM).

Journal of Clinical Oncology2015-05-203 citations

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

2012-11-2133 citations

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.

2010-09-1522 citations

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

2008-05-0161 citations